Psoriatic Arthritis Pipeline Analysis Report 2025
Description
According to the National Psoriasis Foundation, approximately 30% of people who have psoriasis are also affected by psoriatic arthritis globally. This constitutes around 37.5 million people around the world. There are several various types of psoriatic arthritis, therefore finding effective solutions for the disease often requires multiple clinical trials. Several medications are in the pipeline and companies are developing effective and innovative treatments to manage the disease.
Report Coverage
The Psoriatic Arthritis Drug Pipeline Report by Expert Market Research gives comprehensive insights into ongoing psoriatic arthritis clinical trials. It covers various aspects related to the details of psoriatic arthritis drugs under development. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The psoriatic arthritis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from psoriatic arthritis.
The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing psoriatic arthritis pipeline development activities are covered. Moreover, psoriatic arthritis collaborations and commercial assessments are offered, helping stakeholders to make informed decisions.
Psoriatic Arthritis Pipeline Outlook
Psoriatic arthritis is a type of arthritis that is linked to psoriasis. Psoriasis is a chronic skin condition characterized by skin rashes, joint pain, stiffness, and changes in fingernails and toenails. Psoriatic arthritis has similar symptoms to rheumatoid arthritis , but it affects fewer joints than rheumatoid arthritis. There are several types of psoriatic arthritis and can be divided into five categories which include arthritis affecting small joints in the toes and fingers, asymmetrical arthritis of the joints in the hands, symmetrical polyarthritis, and arthritis mutilans (a rare type of arthritis that deforms joints) and psoriatic spondylitis which affects the lower back and spine.
The common symptoms of psoriatic arthritis include joint pain, stiffness, and redness near affected joints, swelling in fingers, pain where tendons and ligaments attach to the bones, silver or gray scaly patches on the scalp, knees, and elbows, knees, and discoloration or pitting on fingernails among others. The psoriatic arthritis treatment options include anti-inflammatory medicine like NSAIDs or acetaminophen, corticosteroids, cold or heat therapy, disease-modifying antirheumatic drugs (DMARDs) and physical therapy.
Several pharma companies and institutes are developing innovative treatments to manage psoriatic arthritis. There have been significant increases in the treatment options for psoriatic arthritis. Between 2013 and 2017, the FDA approved three new drugs to manage and treat psoriatic arthritis after clinical trials showed positive results. Researchers are exploring potential new therapies in clinical trials to manage the disease, thus impacting the psoriatic arthritis pipeline analysis.
Psoriatic Arthritis – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of psoriatic arthritis drug candidates based on several segmentations including:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
EMR’s psoriatic arthritis therapeutic assessment report covers 50+ drug analyses based on drug classes:
EMR’s pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total clinical trials for psoriatic arthritis with 108 pipeline drugs in phase III.
Psoriatic Arthritis – Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under psoriatic arthritis pipeline analysis include recombinant fusion proteins, small molecules, monoclonal antibodies, peptides, polymers, and gene therapy. Gene therapy is a promising treatment for arthritis. It is an experimental technique to treat or prevent disease by introducing genetic material into cells to compensate for abnormal genes and replacing them with a healthy copy of the gene. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for psoriatic arthritis.
Psoriatic Arthritis Clinical Trials Assessment – Competitive Dynamics
The EMR psoriatic arthritis drug report insights involve the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in Psoriatic Arthritis clinical trials:
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for psoriatic arthritis. It covers product description, trial ID, study type, drug class, mode of administration, and recruitment status of psoriatic arthritis drug candidates.
Drug: Izokibep
The trial is designed to evaluate the safety and effectiveness of Izokibep which is a selective inhibitor of interleukin (IL)-17A for the treatment of psoriatic arthritis (PsA). The trial is sponsored by Hansoh BioMedical R&D Company and is currently under phase II.
Drug: HS-10374
The objective of the study is to explore the clinical safety and effectiveness of HS-10374 for the treatment of active psoriatic arthritis. The trial is sponsored by ACELYRIN Inc. and is currently under phase III.
Biological: Secukinumab
Novartis Pharmaceuticals is developing this psoriatic arthritis drug candidate and it is currently under phase III. The study is being conducted to compare the safety and effectiveness of secukinumab and ustekinumab in patients with active psoriatic arthritis.
Reasons To Buy This Report
The Psoriatic Arthritis Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for psoriatic arthritis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into psoriatic arthritis collaborations, regulatory environments, and potential growth opportunities within the treatment landscape.
Key Questions Answered in the Psoriatic Arthritis – Pipeline Assessment Report
Psoriatic Arthritis Treatment Market
Canine Arthritis Treatment Market
Rheumatoid Arthritis Therapeutics Market
Report Coverage
The Psoriatic Arthritis Drug Pipeline Report by Expert Market Research gives comprehensive insights into ongoing psoriatic arthritis clinical trials. It covers various aspects related to the details of psoriatic arthritis drugs under development. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The psoriatic arthritis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from psoriatic arthritis.
The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing psoriatic arthritis pipeline development activities are covered. Moreover, psoriatic arthritis collaborations and commercial assessments are offered, helping stakeholders to make informed decisions.
Psoriatic Arthritis Pipeline Outlook
Psoriatic arthritis is a type of arthritis that is linked to psoriasis. Psoriasis is a chronic skin condition characterized by skin rashes, joint pain, stiffness, and changes in fingernails and toenails. Psoriatic arthritis has similar symptoms to rheumatoid arthritis , but it affects fewer joints than rheumatoid arthritis. There are several types of psoriatic arthritis and can be divided into five categories which include arthritis affecting small joints in the toes and fingers, asymmetrical arthritis of the joints in the hands, symmetrical polyarthritis, and arthritis mutilans (a rare type of arthritis that deforms joints) and psoriatic spondylitis which affects the lower back and spine.
The common symptoms of psoriatic arthritis include joint pain, stiffness, and redness near affected joints, swelling in fingers, pain where tendons and ligaments attach to the bones, silver or gray scaly patches on the scalp, knees, and elbows, knees, and discoloration or pitting on fingernails among others. The psoriatic arthritis treatment options include anti-inflammatory medicine like NSAIDs or acetaminophen, corticosteroids, cold or heat therapy, disease-modifying antirheumatic drugs (DMARDs) and physical therapy.
Several pharma companies and institutes are developing innovative treatments to manage psoriatic arthritis. There have been significant increases in the treatment options for psoriatic arthritis. Between 2013 and 2017, the FDA approved three new drugs to manage and treat psoriatic arthritis after clinical trials showed positive results. Researchers are exploring potential new therapies in clinical trials to manage the disease, thus impacting the psoriatic arthritis pipeline analysis.
Psoriatic Arthritis – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of psoriatic arthritis drug candidates based on several segmentations including:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
EMR’s psoriatic arthritis therapeutic assessment report covers 50+ drug analyses based on drug classes:
- Recombinant Fusion Proteins
- Small Molecule
- Monoclonal Antibody
- Peptide
- Polymer
- Gene Therapy
EMR’s pipeline assessment report covers 50+ drug analyses based on the route of administration.
- Oral
- Parenteral
- Others
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total clinical trials for psoriatic arthritis with 108 pipeline drugs in phase III.
Psoriatic Arthritis – Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under psoriatic arthritis pipeline analysis include recombinant fusion proteins, small molecules, monoclonal antibodies, peptides, polymers, and gene therapy. Gene therapy is a promising treatment for arthritis. It is an experimental technique to treat or prevent disease by introducing genetic material into cells to compensate for abnormal genes and replacing them with a healthy copy of the gene. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for psoriatic arthritis.
Psoriatic Arthritis Clinical Trials Assessment – Competitive Dynamics
The EMR psoriatic arthritis drug report insights involve the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in Psoriatic Arthritis clinical trials:
- ACELYRIN Inc.
- Hansoh BioMedical R&D Company
- Novartis Pharmaceuticals
- MoonLake Immunotherapeutics AG
- Aclaris Therapeutics, Inc.
- Ventyx Biosciences, Inc
- Enlivex Therapeutics Ltd.
- AbbVie
- Janssen Research & Development, LLC
- Others
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for psoriatic arthritis. It covers product description, trial ID, study type, drug class, mode of administration, and recruitment status of psoriatic arthritis drug candidates.
Drug: Izokibep
The trial is designed to evaluate the safety and effectiveness of Izokibep which is a selective inhibitor of interleukin (IL)-17A for the treatment of psoriatic arthritis (PsA). The trial is sponsored by Hansoh BioMedical R&D Company and is currently under phase II.
Drug: HS-10374
The objective of the study is to explore the clinical safety and effectiveness of HS-10374 for the treatment of active psoriatic arthritis. The trial is sponsored by ACELYRIN Inc. and is currently under phase III.
Biological: Secukinumab
Novartis Pharmaceuticals is developing this psoriatic arthritis drug candidate and it is currently under phase III. The study is being conducted to compare the safety and effectiveness of secukinumab and ustekinumab in patients with active psoriatic arthritis.
Reasons To Buy This Report
The Psoriatic Arthritis Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for psoriatic arthritis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into psoriatic arthritis collaborations, regulatory environments, and potential growth opportunities within the treatment landscape.
Key Questions Answered in the Psoriatic Arthritis – Pipeline Assessment Report
- Which companies/institutions are leading the psoriatic arthritis drug development?
- What is the efficacy and safety profile of psoriatic arthritis pipeline drugs?
- Which company is leading the psoriatic arthritis pipeline development activities?
- What is the current psoriatic arthritis commercial assessment?
- What are the opportunities and challenges present in the psoriatic arthritis drug pipeline landscape?
- What is the efficacy and safety profile of psoriatic arthritis pipeline drugs?
- Which company is conducting major trials for psoriatic arthritis drugs?
- Which companies/institutions are involved in psoriatic arthritis collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in psoriatic arthritis?
Psoriatic Arthritis Treatment Market
Canine Arthritis Treatment Market
Rheumatoid Arthritis Therapeutics Market
Table of Contents
200 Pages
- 1 Preface
- 1.1 Introduction
- 1.2 Objectives of the Study
- 1.3 Research Methodology and Assumptions
- 2 Executive Summary
- 3 Overview of Psoriatic Arthritis
- 3.1 Signs and Symptoms
- 3.2 Causes
- 3.3 Risk Factors
- 3.4 Types of Psoriatic Arthritis
- 3.5 Diagnosis
- 3.6 Treatment
- 4 Patient Profile: Psoriatic Arthritis
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Psoriatic Arthritis: Epidemiology Snapshot
- 5.1 Psoriatic Arthritis Incidence by Key Markets
- 5.2 Psoriatic Arthritis – Patients Seeking Treatment in Key Markets
- 6 Psoriatic Arthritis: Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 7 Psoriatic Arthritis: Key Facts Covered
- 7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
- 7.2 Top Countries Contributing to Clinical Trials in Europe
- 7.3 Top Countries Contributing to Clinical Trials in North America
- 7.4 Top Countries Contributing to Clinical Trials in Other Regions
- 8 Psoriatic Arthritis, Drug Pipeline Assessment
- 8.1 Assessment by Treatment Type
- 8.2 Assessment by Route of Administration
- 8.3 Assessment by Drug Class
- 9 EMR Drug Pipeline Comparative Analysis
- 9.1 List of Psoriatic Arthritis Pipeline Drugs
- 9.1.1 By Company
- 9.1.2 By Phase
- 9.1.3 By Indication
- 9.1.4 By Trial Status
- 9.1.5 By Funder Type
- 9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
- 10 Psoriatic Arthritis Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
- 10.1 Comparative Analysis for Late-Stage Drugs
- 10.1.1 Study Type
- 10.1.2 Recruitment Status
- 10.1.3 Company
- 10.1.4 Funder Type
- 10.2 Product Level Analysis*
- 10.2.1 Izokibep
- 10.2.1.1 Product Description
- 10.2.1.2 Trial ID
- 10.2.1.3 Sponsor Name
- 10.2.1.4 Study Type
- 10.2.1.5 Drug Class
- 10.2.1.6 Eligibility Criteria
- 10.2.1.7 Study Record Dates
- 10.2.1.7.1 First Submitted
- 10.2.1.7.2 First Posted
- 10.2.1.7.3 Last Update Posted
- 10.2.1.7.4 Last Verified
- 10.2.1.8 Indication
- 10.2.1.9 Study Design
- 10.2.1.10 Recruitment Status
- 10.2.1.11 Enrollment (Estimated)
- 10.2.1.12 Location Countries
- 10.2.1.13 Recent Results
- 10.2.2 Secukinumab
- 10.2.3 Apremilast
- 10.2.4 Other Drugs
- 11 Psoriatic Arthritis Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
- 11.1 Comparative Analysis for Mid-Stage Drugs
- 11.1.1 Study Type
- 11.1.2 Recruitment Status
- 11.1.3 Company
- 11.1.4 Funder Type
- 11.2 Product Level Analysis*
- 11.2.1 Adalimumab
- 11.2.1.1 Product Description
- 11.2.1.2 Trial ID
- 11.2.1.3 Sponsor Name
- 11.2.1.4 Study Type
- 11.2.1.5 Drug Class
- 11.2.1.6 Eligibility Criteria
- 11.2.1.7 Study Record Dates
- 11.2.1.7.1 First Submitted
- 11.2.1.7.2 First Posted
- 11.2.1.7.3 Last Update Posted
- 11.2.1.7.4 Last Verified
- 11.2.1.8 Indication
- 11.2.1.9 Study Design
- 11.2.1.10 Recruitment Status
- 11.2.1.11 Enrollment (Estimated)
- 11.2.1.12 Location Countries
- 11.2.1.13 Recent Results
- 11.2.2 Izokibep
- 11.2.3 Other Drugs
- 12 Psoriatic Arthritis Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
- 12.1 Comparative Analysis for Early-Stage Drugs
- 12.1.1 Study Type
- 12.1.2 Recruitment Status
- 12.1.3 Company
- 12.1.4 Funder Type
- 12.2 Product Level Analysis*
- 12.2.1 Allocetra
- 12.2.1.1 Product Description
- 12.2.1.2 Trial ID
- 12.2.1.3 Sponsor Name
- 12.2.1.4 Study Type
- 12.2.1.5 Drug Class
- 12.2.1.6 Eligibility Criteria
- 12.2.1.7 Study Record Dates
- 12.2.1.7.1 First Submitted
- 12.2.1.7.2 First Posted
- 12.2.1.7.3 Last Update Posted
- 12.2.1.7.4 Last Verified
- 12.2.1.8 Indication
- 12.2.1.9 Study Design
- 12.2.1.10 Recruitment Status
- 12.2.1.11 Enrollment (Estimated)
- 12.2.1.12 Location Countries
- 12.2.2 Rituximab
- 12.2.3 Other Drugs
- 13 Psoriatic Arthritis Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
- 13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
- 13.1.1 Study Type
- 13.1.2 Recruitment Status
- 13.1.3 Company
- 13.1.4 Funder Type
- 13.2 Product Level Analysis*
- 13.2.1
- 13.2.1.1 Product Description
- 13.2.1.2 Trial ID
- 13.2.1.3 Sponsor Name
- 13.2.1.4 Study Type
- 13.2.1.5 Drug Class
- 13.2.1.6 Eligibility Criteria
- 13.2.1.7 Study Record Dates
- 13.2.1.7.1 First Submitted
- 13.2.1.7.2 First Posted
- 13.2.1.7.3 Last Update Posted
- 13.2.1.7.4 Last Verified
- 13.2.1.8 Indication
- 13.2.1.9 Study Design
- 13.2.1.10 Recruitment Status
- 13.2.1.11 Enrollment (Estimated)
- 13.2.1.12 Location Countries
- 13.2.2 Other Drugs
- 14 Psoriatic Arthritis, Key Drug Pipeline Companies
- 14.1 ACELYRIN Inc.
- 14.1.1 Company Snapshot
- 14.1.2 Pipeline Product Portfolio
- 14.1.3 Financial Analysis
- 14.1.4 Recent News and Developments
- 14.2 Hansoh BioMedical R&D Company
- 14.2.1 Company Snapshot
- 14.2.2 Pipeline Product Portfolio
- 14.2.3 Financial Analysis
- 14.2.4 Recent News and Developments
- 14.3 Novartis Pharmaceuticals
- 14.3.1 Company Snapshot
- 14.3.2 Pipeline Product Portfolio
- 14.3.3 Financial Analysis
- 14.3.4 Recent News and Developments
- 14.4 MoonLake Immunotherapeutics AG
- 14.4.1 Company Snapshot
- 14.4.2 Pipeline Product Portfolio
- 14.4.3 Financial Analysis
- 14.4.4 Recent News and Developments
- 14.5 Aclaris Therapeutics, Inc.
- 14.5.1 Company Snapshot
- 14.5.2 Pipeline Product Portfolio
- 14.5.3 Financial Analysis
- 14.5.4 Recent News and Developments
- 14.6 Ventyx Biosciences, Inc
- 14.6.1 Company Snapshot
- 14.6.2 Pipeline Product Portfolio
- 14.6.3 Financial Analysis
- 14.6.4 Recent News and Developments
- 14.7 Enlivex Therapeutics Ltd.
- 14.7.1 Company Snapshot
- 14.7.2 Pipeline Product Portfolio
- 14.7.3 Financial Analysis
- 14.7.4 Recent News and Developments
- 14.8 AbbVie
- 14.8.1 Company Snapshot
- 14.8.2 Pipeline Product Portfolio
- 14.8.3 Financial Analysis
- 14.8.4 Recent News and Developments
- 14.9 Janssen Research & Development, LLC
- 14.9.1 Company Snapshot
- 14.9.2 Pipeline Product Portfolio
- 14.9.3 Financial Analysis
- 14.9.4 Recent News and Developments
- 15 Regulatory Framework for Drug Approval, By Region
- 16 Terminated or Suspended Pipeline Products
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
